Back to results
US 5,670,514 AGranted
Compositions for inhibiting bone loss
AssigneeEli Lilly and Company
InventorsJames E. Audia, Blake L. Neubauer
Life of this patent
Estimating the term…
Abstract
The present invention provides methods of inhibiting bone loss in mammals via the administration to a mammal in need of such treatment an effective amount of a compound from a series of benzoquinolin-3-ones. Such compounds also are sequentially or concurrently coadministered with a bone antiresorptive agent or a bone anabolic agent.
Claims5
A pharmaceutical composition comprising a compound of formula I ##STR13## wherein R and R.sup.1 both represent hydrogen or combine to form a bond;
- R.sup.2 represents hydrogen or C.sub.1 -C.sub.3 alkyl;
- R.sup.3 represents hydrogen, methyl or ethyl;
- either R.sup.4 and X--R.sup.5 have the following definitions, (R.sup.6).sub.m is absent, and R.sup.3 does not represent hydrogen;
- or (R.sup.6).sub.m has the following definition, R.sup.4 and X--R.sup.5 are absent, and R.sup.3 does not represent ethyl;
- R.sup.4 and --X--R.sup.5 each occupies one of the 7-, 8- and 9-positions;
- R.sup.4 represents hydrogen, halo, methyl or ethyl;
- X represents C.sub.1 -C.sub.4 alkyl, C.sub.2 -C.sub.4 alkenyl, C.sub.2 -C.sub.4 alkynyl, a bond --SO--, --SO.sub.2 --, --CO--Y--(CH.sub.2).sub.n --, --Y--CO--(CH.sub.2).sub.n, --CO--, --Z--(CH.sub.2).sub.n --, or --SO.sub.3 --;
- wherein X groups which are not symmetrical may be in either orientation;
- Y represents --S--, --O--, or --NH--;
- Z represents --O-- or --S--;
- n represents 0-3;
- R.sup.5 represents phenyl, naphthalenyl, pyridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, anthracenyl, acenaphthalenyl, thiazolyl, benzimidazolyl, indazolyl, thiophenyl, phenanthrenyl, quinolinyl, fluorenyl, isoquinolinyl, indanyl, benzopyranyl, indolyl, benzisoquinolinyl, benzindolyl, benzothiazolyl, benzothiophenyl, quinoxalinyl, benzoxazolyl, tetrazolyl, naphthothiazolyl, quinazolinyl, thiazolopyridinyl, pyridazinoquinazolinyl, benzisothiazolyl, benzodioxolyl, benzodioxinyl, diphenylmethyl or triphenylmethyl;
- the above R.sup.5 groups are unsubstituted or substituted with 1-3 groups chosen from the group consisting of halo, trifluoromethyl, trifluoroethoxy, C.sub.1 -C.sub.4 alkyl, trifluoromethoxy, hydroxy, C.sub.1 -C.sub.3 alkoxy, nitro, C.sub.1 -C.sub.3 alkylthio, C.sub.1 -C.sub.6 alkanoyl, phenyl, oxo, phenoxy, phenylthio, C.sub.1 -C.sub.3 alkylsulfinyl, C.sub.1 -C.sub.3 alkylsulfonyl, cyano, amino, C.sub.1 -C.sub.3 alkylamino, diphenylmethylamino, triphenylmethylamino, benzyloxy, benzylthio, (mono-halo, nitro or CF.sub.3)benzyl(oxy or thio), di(C.sub.1 -C.sub.3 alkyl, C.sub.3 -C.sub.6 cycloalkyl, or C.sub.4 -C.sub.8 cycloalkylalkyl)amino, (mono-C.sub.1 -C.sub.3 alkyl, C.sub.1 -C.sub.3 alkoxy or halo)-(phenyl, phenoxy, phenylthio, phenylsulfonyl or phenoxysulfonyl), C.sub.2 -C.sub.6 alkanoylamino, benzoylamino, diphenylmethylamino(C.sub.1 -C.sub.3 alkyl), aminocarbonyl, C.sub.1 -C.sub.3 alkylaminocarbonyl, di(C.sub.1 -C.sub.3 alkyl)aminocarbonyl, halo-C.sub.1 -C.sub.6 alkanoyl, aminosulfonyl, C.sub.1 -C.sub.3 alkylaminosulfonyl, di(C.sub.1 -C.sub.3 alkyl)aminosulfonyl, phenyl(oxy or thio) (C.sub.1 -C.sub.3 alkyl), (halo, C.sub.1 -C.sub.3 alkyl or C.sub.1 -C.sub.3 alkoxy)phenyl(oxy or thio) (C.sub.1 -C.sub.3 alkyl), benzoyl, or (amino, C.sub.1 -C.sub.3 alkylamino or di(C.sub.1 -C.sub.3 alkyl)amino) (C.sub.1 -C.sub.3 alkyl);
- or an above R.sup.5 group is substituted with a morpholino(C.sub.1 -C.sub.3 alkyl) group, a phenyl(C.sub.1 -C.sub.3 alkyl)piperidinyl group, a phenyl(C.sub.1 -C.sub.3 alkyl)-piperidinylaminocarbonyl group, a C.sub.2 -C.sub.6 alkanoyl-aminothiophenyl group, or a (amino, C.sub.1 -C.sub.3 alkylamino or di(C.sub.1 -C.sub.3 alkyl)amino)naphthalenylsulfonylamino group;
- or R.sup.5 is a perhalophenyl group;
- m represents 1-2;
- R.sup.6 represents hydrogen, halogen, NO.sub.2, cyano, CF.sub.3, C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, carboxy, C.sub.1 -C.sub.6 alkoxycarbonyl, amino, C.sub.1 -C.sub.4 alkylamino, C.sub.1 -C.sub.4 dialkylamino, amido, C.sub.1 -C.sub.4 alkylamido, C.sub.1 -C.sub.4 dialkylamido, mercapto, C.sub.1 -C.sub.6 alkylthio, C.sub.1 -C.sub.6 alkylsulfinyl, C.sub.1 -C.sub.6 alkylsulfonyl, or a group --A--R.sup.7 where A is C.sub.1 -C.sub.6 alkylene C.sub.2 -C.sub.6 alkenylene or C.sub.2 -C.sub.6 alkynylene;
- and R.sup.7 represents halogen, hydroxy, CF.sub.3, C.sub.1 -C.sub.6 alkoxy, carboxy, C.sub.1 -C.sub.6 alkoxycarbonyl, amino, C.sub.1 -C.sub.4 alkylamino, C.sub.1 -C.sub.4 dialkylamino, amido, C.sub.1 -C.sub.4 alkylamido, C.sub.1 -C.sub.4 dialkylamido, C.sub.1 -C.sub.4 alkylsulfonylamino, aminosulfonyl or C.sub.1 -C.sub.4 alkylaminosulfonyl;
- or a pharmaceutically acceptable salt thereof, and an effective amount of a bone antiresorptive agent, in combination with a pharmaceutically acceptable carrier, diluent, or excipient.
16 more elements
A pharmaceutical composition comprising a compound of formula I ##STR14## wherein R and R.sup.1 both represent hydrogen or combine to form a bond;
- R.sup.2 represents hydrogen or C.sub.1 -C.sub.3 alkyl;
- R.sup.3 represents hydrogen, methyl or ethyl;
- either R.sup.4 and X--R.sup.5 have the following definitions, (R.sup.6).sub.m is absent, and R.sup.3 does not represent hydrogen;
- or (R.sup.6).sub.m has the following definition, R.sup.4 and X--R.sup.5 are absent, and R.sup.3 does not represent ethyl;
- R.sup.4 and --X--R.sup.5 each occupies one of the 7-, 8- and 9-positions;
- R.sup.4 represents hydrogen, halo, methyl or ethyl;
- X represents C.sub.1 -C.sub.4 alkyl, C.sub.2 -C.sub.4 alkenyl, C.sub.2 -C.sub.4 alkynyl, a bond, --SO--, --SO.sub.2 --, --CO--Y--(CH.sub.2).sub.n, --Y--CO--(CH.sub.2).sub.n, --CO--, --Z --(CH.sub.2).sub.n --, or --SO.sub.3 --;
- wherein X groups which are not symmetrical may be in either orientation;
- Y represents --S--, --O--, or --NH--;
- Z represents --O--or --S--;
- n represents 0-3;
- R.sup.5 represents phenyl, naphthalenyl, pyridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, anthracenyl, acenaphthalenyl, thiazolyl, benzimidazolyl, indazolyl, thiophenyl, phenanthrenyl, quinolinyl, fluorenyl, isoquinolinyl, indanyl, benzopyranyl, indolyl, benzisoquinolinyl, benzindolyl, benzothiazolyl, benzothiophenyl, quinoxalinyl, benzoxazolyl, tetrazolyl, naphthothiazolyl, quinazolinyl, thiazolopyridinyl, pyridazinoquinazolinyl, benzisothiazolyl, benzodioxolyl, benzodioxinyl, diphenylmethyl or triphenylmethyl;
- the above R.sup.5 groups are unsubstituted or substituted with 1-3 groups chosen from the group consisting of halo, trifluoromethyl, trifluoroethoxy, C.sub.1 -C.sub.4 alkyl, trifluoromethoxy, hydroxy, C.sub.1 -C.sub.3 alkoxy, nitro, C.sub.1 -C.sub.3 alkylthio, C.sub.1 -C.sub.6 alkanoyl, phenyl, oxo, phenoxy, phenylthio, C.sub.1 -C.sub.3 alkylsulfinyl, C.sub.1 -C.sub.3 alkylsulfonyl, cyano, amino, C.sub.1 -C.sub.3 alkylamino, diphenylmethylamino, triphenylmethylamino, benzyloxy, benzylthio, (mono-halo, nitro or CF.sub.3)benzyl(oxy or thio), di(C.sub.1 -C.sub.3 alkyl, C.sub.3 -C.sub.6 cycloalkyl, or C.sub.4 -C.sub.8 cycloalkylalkyl)amino, (mono-C.sub.1 -C.sub.3 alkyl, C.sub.1 -C.sub.3 alkoxy or halo)-(phenyl, phenoxy, phenylthio, phenylsulfonyl or phenoxysulfonyl), C.sub.2 -C.sub.6 alkanoylamino, benzoylamino, diphenylmethylamino(C.sub.1 -C.sub.3 alkyl), aminocarbonyl, C.sub.1 -C.sub.3 alkylaminocarbonyl, di(C.sub.1 -C.sub.3 alkyl)aminocarbonyl, halo-C.sub.1 -C.sub.6 alkanoyl, aminosulfonyl, C.sub.1 -C.sub.3 alkylaminosulfonyl, di(C.sub.1 -C.sub.3 alkyl)aminosulfonyl, phenyl(oxy or thio) (C.sub.1 -C.sub.3 alkyl), (halo, C.sub.1 -C.sub.3 alkyl or C.sub.1 -C.sub.3 alkoxy)phenyl(oxy or thio) (C.sub.1 -C.sub.3 alkyl), benzoyl, or (amino, C.sub.1 -C.sub.3 alkylamino or di(C.sub.1 -C.sub.3 alkyl)amino) (C.sub.1 -C.sub.3 alkyl);
- or an above R.sup.5 group is substituted with a morpholino (C.sub.1 -C.sub.3 alkyl) group, a phenyl (C.sub.1 -C.sub.3 alkyl)piperidinyl group, a phenyl (C.sub.1 -C.sub.3 alkyl)-piperidinylaminocarbonyl group, a C.sub.2 -C.sub.6 alkanoyl-aminothiophenyl group, or a (amino, C.sub.1 -C.sub.3 alkylamino or di(C-C.sub.3 alkyl)amino)naphthalenylsulfonylamino group;
- or R.sup.5 is a perhalophenyl group;
- m represents 1-2;
- R.sup.6 represents hydrogen, halogen, NO.sub.2, cyano, CF.sub.3, C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, carboxy, C.sub.1 -C.sub.6 alkoxycarbonyl, amino, C.sub.1 -C.sub.4 alkylamino, C.sub.1 -C.sub.4 dialkylamino, amido, C.sub.1 -C.sub.4 alkylamido, C.sub.1 -C.sub.4 dialkylamido, mercapto, C.sub.1 -C.sub.6 alkylthio, C.sub.1 -C.sub.6 alkylsulfinyl, C.sub.1 -C.sub.6 alkylsulfonyl, or a group --A--R.sup.7 where A is C.sub.1 -C.sub.6 alkylene C.sub.2 -C.sub.6 C.sub.6 alkenylene or C.sub.2 -C.sub.6 alkynylene;
- and R.sup.7 represents halogen, hydroxy, CF.sub.3, C.sub.1 -C.sub.6 alkoxy, carboxy, C.sub.1 -C.sub.6 alkoxycarbonyl, amino, C.sub.1 -C.sub.4 alkylamino, C.sub.1 -C.sub.4 dialkylamino, amido, C.sub.1 -C.sub.4 alkylamido, C.sub.1 -C.sub.4 dialkylamido, C.sub.1 -C.sub.4 alkylsulfonylamino, aminosulfonyl or C.sub.1 -C.sub.4 alkylaminosulfonyl;
- or a pharmaceutically acceptable salt thereof, and an effective amount of a bone anabolic agent, in combination with a pharmaceutically acceptable carrier, diluent, or excipient.
16 more elements
A pharmaceutical composition comprising (-)-(4aR)-(10bR)-8-chloro-4-methyl-1,2,3,4,4a,5,6,10b-octahydrobenzof!-qu inolin-3-one, or a pharmaceutically acceptable salt thereof, and raloxifene or a pharmaceutically acceptable sale thereof, in combination with a pharmaceutically acceptable carrier, diluent or excipient.
Dependencies are inferred from the claim text.